| __timestamp | Bausch Health Companies Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 7461000 |
| Thursday, January 1, 2015 | 2682700000 | 13047000 |
| Friday, January 1, 2016 | 2810000000 | 11253000 |
| Sunday, January 1, 2017 | 2582000000 | 13933000 |
| Monday, January 1, 2018 | 2473000000 | 29514000 |
| Tuesday, January 1, 2019 | 2554000000 | 37121000 |
| Wednesday, January 1, 2020 | 2367000000 | 67929000 |
| Friday, January 1, 2021 | 2624000000 | 118818000 |
| Saturday, January 1, 2022 | 2625000000 | 159371000 |
| Sunday, January 1, 2023 | 2917000000 | 213894000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to cost management.
From 2014 to 2023, Bausch Health's SG&A expenses have shown a steady increase, peaking at nearly 2.9 billion USD in 2023, reflecting a 44% rise from 2014. This trend underscores their expansive operational strategy. In contrast, BioCryst Pharmaceuticals, Inc. has seen a dramatic surge in SG&A expenses, skyrocketing by over 2700% from 2014 to 2023, reaching approximately 214 million USD. This sharp increase highlights their aggressive growth and investment in administrative capabilities.
These insights reveal the strategic financial maneuvers of two distinct players in the pharmaceutical sector, offering a window into their operational priorities and market positioning.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.